Si-Bone Inc (SIBN) - Net Assets
Based on the latest financial reports, Si-Bone Inc (SIBN) has net assets worth $178.94 Million USD as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($242.72 Million) and total liabilities ($63.78 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check Si-Bone Inc tangible net worth ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $178.94 Million |
| % of Total Assets | 73.72% |
| Annual Growth Rate | N/A |
| 5-Year Change | 32.07% |
| 10-Year Change | N/A |
| Growth Volatility | 1094.79 |
Si-Bone Inc - Net Assets Trend (2013–2025)
This chart illustrates how Si-Bone Inc's net assets have evolved over time, based on quarterly financial data. See Si-Bone Inc liquidity coverage in days to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Si-Bone Inc (2013–2025)
The table below shows the annual net assets of Si-Bone Inc from 2013 to 2025. For live valuation and market cap data, see SIBN stock market capitalisation.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | $177.53 Million | +6.33% |
| 2024-12-31 | $166.96 Million | -1.42% |
| 2023-12-31 | $169.38 Million | +72.30% |
| 2022-12-31 | $98.30 Million | -26.87% |
| 2021-12-31 | $134.42 Million | -20.63% |
| 2020-12-31 | $169.36 Million | +168.80% |
| 2019-12-31 | $63.01 Million | -30.14% |
| 2018-12-31 | $90.19 Million | +169.71% |
| 2017-12-31 | $-129.38 Million | -18.99% |
| 2016-12-31 | $-108.73 Million | -3463.22% |
| 2015-12-31 | $3.23 Million | -53.09% |
| 2014-12-31 | $6.89 Million | +516.94% |
| 2013-12-31 | $-1.65 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to Si-Bone Inc's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 41012200000.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | $626.97 Million | 353.16% |
| Other Comprehensive Income | $816.00K | 0.46% |
| Total Equity | $177.53 Million | 100.00% |
Si-Bone Inc Competitors by Market Cap
The table below lists competitors of Si-Bone Inc ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Symphony Limited
NSE:SYMPHONY
|
$513.77 Million |
|
Capital Bancorp
NASDAQ:CBNK
|
$513.84 Million |
|
Sunrise Energy Metals Ltd
AU:SRL
|
$513.85 Million |
|
Cytek Biosciences Inc
NASDAQ:CTKB
|
$513.99 Million |
|
Perusahaan Perkebunan London Sumatra Indonesia Tbk PT
JK:LSIP
|
$513.52 Million |
|
MIDEA REAL HLDG HD 1
F:MR9
|
$513.51 Million |
|
MH Robot & Automation Co. Ltd.
SHE:301199
|
$513.28 Million |
|
Zhejiang Yueling Co Ltd
SHE:002725
|
$513.21 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Si-Bone Inc's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 166,964,000 to 177,532,000, a change of 10,568,000 (6.3%).
- Net loss of 18,908,000 reduced equity.
- Share repurchases of 2,207,000 reduced equity.
- Other comprehensive income increased equity by 572,000.
- Other factors increased equity by 31,111,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-18.91 Million | -10.65% |
| Share Repurchases | $2.21 Million | -1.24% |
| Other Comprehensive Income | $572.00K | +0.32% |
| Other Changes | $31.11 Million | +17.52% |
| Total Change | $- | 6.33% |
Book Value vs Market Value Analysis
This analysis compares Si-Bone Inc's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 3.73x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2013-12-31 | $-0.72 | $15.21 | x |
| 2014-12-31 | $2.58 | $15.21 | x |
| 2015-12-31 | $0.13 | $15.21 | x |
| 2016-12-31 | $-7.02 | $15.21 | x |
| 2017-12-31 | $-9.33 | $15.21 | x |
| 2018-12-31 | $5.67 | $15.21 | x |
| 2019-12-31 | $2.55 | $15.21 | x |
| 2020-12-31 | $5.83 | $15.21 | x |
| 2021-12-31 | $4.06 | $15.21 | x |
| 2022-12-31 | $2.87 | $15.21 | x |
| 2023-12-31 | $4.41 | $15.21 | x |
| 2024-12-31 | $4.03 | $15.21 | x |
| 2025-12-31 | $4.08 | $15.21 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Si-Bone Inc utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -10.65%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -9.41%
- • Asset Turnover: 0.84x
- • Equity Multiplier: 1.34x
- Recent ROE (-10.65%) is above the historical average (-118.43%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2013 | 0.00% | -12.56% | 2.72x | 0.00x | $-5.99 Million |
| 2014 | -403.45% | -69.42% | 1.38x | 4.21x | $-28.50 Million |
| 2015 | -870.83% | -68.38% | 1.14x | 11.15x | $-28.48 Million |
| 2016 | 0.00% | -48.90% | 1.07x | 0.00x | $-9.72 Million |
| 2017 | 0.00% | -48.01% | 1.34x | 0.00x | $-10.10 Million |
| 2018 | -19.35% | -31.51% | 0.40x | 1.54x | $-26.47 Million |
| 2019 | -60.95% | -57.06% | 0.58x | 1.86x | $-44.70 Million |
| 2020 | -25.80% | -59.54% | 0.33x | 1.32x | $-60.63 Million |
| 2021 | -42.09% | -62.75% | 0.47x | 1.42x | $-70.01 Million |
| 2022 | -62.31% | -57.57% | 0.68x | 1.60x | $-71.09 Million |
| 2023 | -25.59% | -31.20% | 0.60x | 1.36x | $-60.27 Million |
| 2024 | -18.51% | -18.49% | 0.73x | 1.38x | $-47.61 Million |
| 2025 | -10.65% | -9.41% | 0.84x | 1.34x | $-36.66 Million |
Industry Comparison
This section compares Si-Bone Inc's net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $1,818,520,110
- Average return on equity (ROE) among peers: -48.87%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Si-Bone Inc (SIBN) | $178.94 Million | 0.00% | 0.36x | $513.67 Million |
| Abbott Laboratories (ABT) | $17.78 Billion | 20.28% | 1.23x | $153.89 Billion |
| Adagio Medical Holdings, Inc Common Stock (ADGM) | $19.91 Million | -270.00% | 1.43x | $15.55 Million |
| Aethlon Medical Inc (AEMD) | $-5.98 Million | 0.00% | 0.00x | $2.51 Million |
| Acutus Medical Inc (AFIB) | $126.58 Million | -80.56% | 0.52x | $903.35K |
| Adapthealth Corp (AHCO) | $280.85 Million | -57.55% | 5.46x | $1.29 Billion |
| 20/20 Biolabs, Inc. Common Stock (AIDX) | $6.89 Million | 30.07% | 0.49x | $6.67 Million |
| Allurion Technologies, Inc. (ALUR) | $-70.49 Million | 0.00% | 0.00x | $7.70 Million |
| Autonomix Medical, Inc. Common Stock (AMIX) | $8.10 Million | -140.88% | 0.21x | $4.44 Million |
| Artivion Inc (AORT) | $17.90 Million | 7.26% | 0.20x | $1.03 Billion |
| Apyx Medical Inc (APYX) | $22.89 Million | 2.69% | 0.23x | $176.29 Million |
About Si-Bone Inc
SI-BONE, Inc., a medical device company, develops procedural solutions for compromised bone, grounded in expertise in biomechanical design and anatomy-specific applications in the United States and internationally. It offers a series of patented titanium implants and the instruments used to implant them, as well as implantable bone products. The company also provides IFUSE, a triangular titanium … Read more